EUVIMEDEUVIMED entdecken
Vergleichsstudie

Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia

Lucinda Robinson iD, Maddison Hamden, Kim Griggs, Sumu Simon, Catherine Hill iD, Vidya Limaye, Susanna Proudman

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16419 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Lucinda Robinson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tocilizumab (TCZ) is increasingly used as a steroid‐sparing agent in giant cell arteritis (GCA), but there are strict Pharmaceutical Benefits Scheme (PBS) restrictions for its use in Australia. Patients who do not meet the PBS criteria can obtain TCZ through public hospital individual patient use (IPU) schemes which may not be universally accessible. We compared patients receiving IPU‐approved TCZ with patients receiving PBS‐subsidised TCZ and found IPU approvals were granted mainly for visual loss, a serious complication of GCA, in patients who otherwise failed to meet PBS criteria. Further studies demonstrating that TCZ is comparatively more effective than prednisolone monotherapy, as well as cost‐effective, are needed to substantiate the rationale for expanding PBS approval criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisAntibodies, Monoclonal, HumanizedHumansAgedFemaleMaleSouth AustraliaAged, 80 and over

Stichwörter der Autor:innen

Pharmaceutical Benefit Schemecomparisongiant cell arteritisindividual patient usetocilizumab

Substanzen

Antibodies, Monoclonal, Humanizedtocilizumab

Autor:innen und Institutionen

  • Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Pharmacy Department, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
  • University of Adelaide, Adelaide, South Australia, Australia.
  • Ophthalmology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.

ORCID-Profile: Lucinda Robinson, Catherine Hill

Zitieren

APA

Robinson, L., Hamden, M., Griggs, K., Simon, S., Hill, C., Limaye, V., & Proudman, S. (2024). Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.16419

Vancouver

Robinson L, Hamden M, Griggs K, Simon S, Hill C, Limaye V, et al. Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia. Internal Medicine Journal. 2024. doi:10.1111/imj.16419

BibTeX
@article{Robinson2024,
  author = {Robinson, Lucinda and Hamden, Maddison and Griggs, Kim and Simon, Sumu and Hill, Catherine and Limaye, Vidya and Proudman, Susanna},
  title = {Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16419}
}
Kostenlos starten →